Bristol Halts Development Of Vinflunine In Bladder Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is in discussions with FDA regarding novel cytotoxic, but does not expect to file an NDA for bladder cancer; vinflunine program also includes lung and breast cancer studies.